8-K: Cencora Announces $50 Million Share Repurchase from Walgreens Boots Alliance

Cencora, Inc. has agreed to repurchase approximately $50 million of its common stock from Walgreens Boots Alliance Holdings LLC in conjunction with Walgreens' sale of Cencora shares under Rule 144.

Summary

• Cencora, Inc. entered into a share repurchase agreement with Walgreens Boots Alliance Holdings LLC on February 6, 2025.
• Cencora agreed to repurchase 204,491 shares of its common stock directly from Walgreens.
• The repurchase price per share matched the price in Walgreens' Rule 144 sale.
• The total repurchase amount was approximately $50 million.
• The repurchase was completed on February 10, 2025, and the shares will be held in treasury.
• Walgreens also sold 1,081,885 shares under Rule 144.
• After these transactions, Walgreens owns 12,570,000 shares, representing about 6.5% of Cencora's outstanding shares.
• Walgreens' remaining shares are still pledged to financial institutions as security for other variable prepaid forward sale contracts.
• Cencora's total outstanding shares as of January 31, 2025, were 193,917,082, which is reduced by the 204,491 shares repurchased.

Sentiment

Score: 7

Explanation: The announcement is generally positive, indicating a return of capital to shareholders and continued confidence in the company's financial health. However, the continued pledging of shares by Walgreens introduces a degree of uncertainty.

Positives

• The share repurchase may signal Cencora's confidence in its financial position and future prospects.
• Using cash on the balance sheet for the repurchase avoids increasing debt.
• The repurchase reduces the number of outstanding shares, potentially increasing earnings per share.
• Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500.

Negatives

• Walgreens' continued pledging of Cencora shares to secure its own obligations could create potential future market overhang.
• The sale by Walgreens may indicate a change in their investment strategy or financial needs.

Risks

• Further sales of Cencora stock by Walgreens could put downward pressure on the share price.
• The variable prepaid forward sale contracts held by Walgreens could lead to further share sales in the future.
• Changes in market conditions or Cencora's performance could impact the effectiveness of the share repurchase program.

Future Outlook

Cencora will hold the repurchased shares in treasury for future corporate purposes.

Industry Context

Share repurchases are a common method for companies to return capital to shareholders and can be viewed positively by the market if the company is perceived to be undervalued. Walgreens reducing its stake in Cencora is part of a broader trend of companies streamlining their portfolios to focus on core businesses.

Comparison to Industry Standards

• Other pharmaceutical distributors, such as McKesson and Cardinal Health, also engage in share repurchase programs.
• The size of the repurchase is relatively small compared to Cencora's market capitalization and annual revenue.
• Walgreens' remaining stake in Cencora is similar to other strategic investments held by large corporations.

Related Party Transactions

• The share repurchase agreement between Cencora and Walgreens Boots Alliance Holdings LLC constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the repurchase positively as it can increase earnings per share.
• Employees are unlikely to be directly impacted by this transaction.
• Customers and suppliers are unlikely to be directly impacted by this transaction.
• Creditors are unlikely to be directly impacted by this transaction.

Key Dates